Results 71 to 80 of about 19,899 (238)

TAB2 Causes Neuronal Damage by Aggravating Microglia‐Mediated Neuroinflammation in Parkinson's Disease

Advanced Science, EarlyView.
In microglia, STAT3 upregulates TAB2, which promotes NF‐κB activation through its NZF domain‐mediated recognition of K63‐linked ubiquitin chains, leading to inflammatory cytokine release and subsequent neuronal injury. Lumacaftor suppresses TAB2 expression and directly binds the TAB2‐NZF domain to interrupt K63 ubiquitin recognition, thereby blocking ...
Yanhao Zhao, Zimeng Huang, Jianing Gao, Aolan Li, Huizhi Wang, Yingchuan Chen, Guanyu Zhu, Xin Zhang, Yin Jiang, Moxuan Zhang, Fangang Meng, Jianguo Zhang, Tingting Du   +12 more
wiley   +1 more source

Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration

Neurobiology of Disease, 2013
Recent studies indicate that the Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) modulates cytoskeletal functions by regulating actin and tubulin dynamics, thereby affecting neurite outgrowth.
Mareike Caesar, Susanne Zach, Coby B. Carlson, Kathrin Brockmann, Thomas Gasser, Frank Gillardon   +5 more
doaj   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Review of the most common LRRK2 mutations and their impact on peripheral inflammation and in the central nervous system

, 2023
openLRKK2 è una proteina espressa in modo preponderante nelle cellule del sistema immunitario ed è stata collegata a vie del segnale che riguardano funzioni delle cellule immunitarie, quali il rilascio di citochine, l’autofagia e la fagocitosi.
ZAMBERLAN, EMMA
core  

Crosstalk Between Parkinson's Disease and Colorectal Cancer: Genetic Mechanisms, Gut Microbiota, and Therapeutic Insights

Health Care Science, EarlyView.
This review elucidates the crosstalk between Parkinson's disease and colorectal cancer, driven by shared genetics (PRKN, PINK1, DJ‐1) involving oxidative stress, cell cycle regulation, and inflammation. It identifies the gut microbiota—via functional amyloids and short‐chain fatty acids (SCFAs)—as a mechanistic bridge, offering insights for dual ...
Jiacheng Ying, Zhengyuan Fang, Cheng Zhang, Xu Liu, Jianzhi Cui, Zezhi Li, Jiayin Tang   +6 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Structural Characterization of LRRK2 Inhibitors

Journal of Medicinal Chemistry, 2015
Kinase inhibition is considered to be an important therapeutic target for LRRK2 mediated Parkinson's disease (PD). Many LRRK2 kinase inhibitors have been reported but have yet to be optimized in order to qualify as drug candidates for the treatment of the disease. In order to start a structure-function analysis of such inhibitors, we mutated the active
Gilsbach, Bernd K., Messias, Ana C., Ito, Genta, Sattler, Michael, Alessi, Dario R., Wittinghofer, Alfred, Kortholt, Arjan   +6 more
openaire   +6 more sources

The role of LRRK2 in cell signalling [PDF]

Biochemical Society Transactions, 2018
Abstract Parkinson's disease (PD) is a common late-onset neurodegenerative disorder known primarily for its motor features. Mutations and risk variants in LRRK2 cause familial and idiopathic forms of PD. Mutations segregating with disease are found in the LRRK2 GTPase and kinase domains, affecting catalytic activity and protein–protein ...
Kirsten Harvey, Tiago F. Outeiro
openaire   +5 more sources

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives

, 2016
Farzaneh Atashrazm,1 Nicolas Dzamko2 1Neuroscience Research Australia, Randwick; 2School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia Abstract: Major advances in understanding how genetics underlies ...
Atashrazm, F, Dzamko N, Dzamko, N, Atashrazm F   +3 more
core   +1 more source

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation [PDF]

, 2016
Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S, and is known to play a role in Parkinson's disease (PD) pathobiology.
Civiero, L., Baekelandt, V., Lobbestael, E., Baekelandt, Veerle, De Wit, Tina, Greggio, E., De Wit, T., GREGGIO, ELISA, Taymans, J-M., CIVIERO, LAURA, Taymans, J. M., Lobbestael, Evy   +11 more
core   +1 more source